{"id":"W4407086441","doi":"10.1080/14712598.2025.2456485","title":"Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Melanoma; Immunotherapy; Nivolumab; Immune checkpoint; Immune system; Medicine; Ipilimumab; Term (time); Cancer research; Pembrolizumab; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001262123,0.0004364353,0.001167862,0.001026334,0.0002060695,0.001080943,0.0006442475,0.001069384,0.003767368],"category_scores_gemma":[0.001652245,0.0001562518,0.0007394148,0.0008528539,0.0003103353,0.001343906,0.0005781934,0.001888558,0.001248743],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005974723,"about_ca_system_score_gemma":0.001418779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009201316,"about_ca_topic_score_gemma":0.002727142,"domain_scores_codex":[0.999606,0.0001204589,0.00004935042,0.0000519437,0.0001315031,0.0000408113],"domain_scores_gemma":[0.9992173,0.0003974135,0.0001099375,0.0000141276,0.0002216103,0.0000396349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001196419,0.0000427832,0.0001818519,0.0210665,0.0001596915,0.0001040256,0.00006114235,0.0003705207,0.0009941023,0.003731839,0.03999867,0.9331691],"study_design_scores_gemma":[0.00004895615,0.0002011788,0.001006819,0.01761403,0.0003112648,0.0008229308,0.0001230065,0.0002390035,0.0003766619,0.004388398,0.9748452,0.00002262046],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001142594,0.9976339,0.0000949633,0.001350963,0.0002330019,0.000003768691,0.00002068238,0.000005608974,0.0005427621],"genre_scores_gemma":[0.001025012,0.9973837,0.0001649455,0.0007809623,0.0002558401,0.000006779749,0.0000339332,0.00000186401,0.0003470001],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003767368,"threshold_uncertainty_score":0.0126031,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1199571868106471,"score_gpt":0.3952485941741423,"score_spread":0.2752914073634951,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}